9 Conclusion
Collectively, the recent data on animal models and initial clinical trials have raised significant hope of developing new and effective therapies for EB. Although the promise of a cure is still elusive, it is evident that several diseasemodifying treatments are emerging and, with further refinement and additional clinical trials, translational research in EB is making a difference and gradually changing lives for the better. The lessons learned in treating RDEB are likely to have significant implications for improving the management of other forms of EB and indeed other genetic diseases.
Acknowledgments
No sources of funding were used to prepare this review. The authors have no conflicts of interest that are directly relevant to the content of this review. Original studies on cell therapy for RDEB in the McGrath laboratory were supported by the UK National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the UK National Health Service, the NIHR, or the UK Department of Health.
Am J Clin Dermatol. 2014;15(1):1-6. © 2014 Adis Springer International Publishing AG
